98%
921
2 minutes
20
Objectives: This study investigated the longitudinal progression of retinal structure and microvasculature over 3 years in patients with relapsing-remitting multiple sclerosis (RRMS) using optical coherence tomography (OCT) and OCT angiography (OCTA). It also explored the correlation between these changes and the Expanded Disability Status Scale (EDSS) scores.
Methods: In this prospective, longitudinal study, we enrolled 66 patients with RRMS without history of optic neuritis and 124 healthy controls. All participants underwent full ophthalmological examination, OCT/OCTA scans, and disability scoring (EDSS) at baseline and after 12 and 24 months. OCT data were analyzed for retinal layer thickness, while OCTA assessed microvascular perfusion in the retinal capillary plexuses and choriocapillaris. Statistical models evaluated yearly rates of change and their association with EDSS scores.
Results: The patients with RRMS exhibited 3.6 times faster thinning of the inner plexiform layer (IPL; - 0.47 µm per year, P = 0.001) compared to controls over 3 years. Additionally, superficial retinal capillary layer perfusion density decreased more rapidly at - 0.44% per year (P = 0.006) in patients with MS. A strong correlation was found between worsening EDSS scores and accelerated ONL thinning (estimated coefficient: - 1.62 µm/per unit change of EDSS score, P = 0.004).
Discussion: This study demonstrates progressive retinal neurodegeneration and microvascular dysfunction in patients with RRMS without a history of optic neuritis. The association between ONL thinning and increased disability supports the potential of OCT/OCTA as valuable tools for monitoring disease progression and severity in RRMS.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11872746 | PMC |
http://dx.doi.org/10.1007/s00415-025-12930-7 | DOI Listing |
Front Immunol
September 2025
Neuroimmunology and Neuroinflammation Group, Biomedical Research Institute of Málaga-IBIMA Plataforma Bionand, Hospital Regional Universitario de Málaga, Málaga, Spain.
Background: Despite progress in serum biomarker research, reliable tools for early diagnosis and patient stratification in multiple sclerosis (MS) remain limited. This study uses proteomic profiling in untreated MS patients to identify early disease-associated biomarkers.
Methods: We conducted an unbiased proteomic screen to capture broad serum protein expression profiles in a well-characterized discovery sample: 7 relapsing remitting MS (RRMS), 7 secondary progressive MS (SPMS), 4 with primary progressive MS (PPMS) alongside 6 healthy controls (HC).
J Neurol Neurosurg Psychiatry
September 2025
Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.
Background: Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly used as a one-off disease-modifying therapy for aggressive forms of multiple sclerosis (MS). We report real-world effectiveness of AHSCT for MS in the UK.
Methods: This retrospective open-label study included patients with (pw)MS treated with AHSCT between 2002 and 2023 in 14 UK centres.
Mult Scler J Exp Transl Clin
September 2025
Department of Neurology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
Background: In relapsing-remitting multiple sclerosis (RRMS), the assessment of clinical disease activity can be challenging.
Objectives: To determine the diagnostic potential of serum neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP) to distinguish a relapse from other causes of deterioration.
Methods: In this multicenter, prospective study, RRMS patients with new neurological symptoms in the last 14 days were followed for 12 weeks.
Brain Commun
August 2025
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
Patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression independent of relapse activity (PIRA), which can be an early sign of secondary progressive MS (SPMS). We defined persistent PIRA as ongoing sustained disability over the entire available follow-up period. However, PIRA events can regress over time.
View Article and Find Full Text PDFJ Neurol
September 2025
Department of Neurology, University Medicine Essen, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Hufelandstr. 55, 45147, Essen, Germany.
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. The presence of other conditions alongside MS imposes a substantial personal and socioeconomic burden. In particular, the impact of comorbid autoimmune diseases (AID) on MS outcomes remains uncertain.
View Article and Find Full Text PDF